A New World of Eczema Treatment
The Dermatologist is excited to publish this special supplement, Eczema & Atopic Dermatitis Treatment Today. It is an exciting time in the development of therapies to treat atopic dermatitis.
It is estimated that 31.6 million people in the United States have eczema, and at least 17.8 million with moderate to severe eczema or atopic dermatitis (AD), according to the National Eczema Association (NEA). The prevalence of childhood eczema/AD in the United States is 10.7% overall and as high as 18.1% in individual states and 21% across various countries. Approximately 1 in 3 children with eczema/AD has moderate to severe disease. However, these statistics could be underestimations.1
For example, one study found that the prevalence of eczema in adults could be as high as 10.2%, which suggests that most children with eczema/AD continue to be affected even in adulthood. Three percent of US adults have moderate to severe eczema/AD requiring systemic therapy. Significant unmet needs exist for the treatment of patients with eczema/AD.2-5
This issue covers the latest news, and highlights notable trends in the industry in research and treatment. The cover story takes a look at New Therapeutics for Eczema and Atopic Dermatitis, including updates on investigational new therapies crisaborole and dupulimab. The landscape for treating AD will likely look very different over the next year as new therapeutics come up for approval.
The article Protecting the Skin Barrier in Atopic Dermatitis focuses on recent research regarding skin barrier protections, using over-the-counter and prescription ointments, lotions, and creams. “The skin barrier is of central importance in AD. For those that have a mutation in a skin structural protein, it makes sense that they have ‘leaky skin’: that allows water to escape unnaturally, but also allows allergens, irritants, and infectious agents to enter. Perhaps more importantly, even those that appear to start with normal skin barrier function can actually develop secondary barrier damage in the presence of inflammation,” said Peter Lio, MD, who practices at Medical Dermatology Associates of Chicago and also serves on the Scientific Advisory Board for the NEA.
Here’s to the future and brighter days for people living with eczema and AD.
Lisa B. Samalonis, Managing Editor
1. Eczema prevalence in the United States. National Eczema Association website. https://nationaleczema.org/research/eczema-prevalence/. Accessed October 4, 2016.
2. Hanifin JM, Reed ML; Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82-91.
3. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health.
J Invest Dermatol. 2011;131(1):67-73.
4. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476-486.
5. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. J Allergy Clin Immunol. 2013;132(5):1132-1138.